Akero Therapeutics, Inc. Company Analysis & Research
Akero has been acquired by Novo Nordisk. Akero Therapeutics engages in developing transformational treatments for patients with serious metabolic diseases, with its lead product candidate being efruxifermin (EFX), an analog of fibroblast growth factor 21 that protects against cellular stress and regulates metabolism for treatment of metabolic dysfunction-associated steatohepatitis (MASH) patients. The company represents a strategic acquisition target in the rapidly growing fatty liver disease treatment market.
Its lead asset, EFX, an FGF21 analog, represents a scientifically distinct approach compared to some competitors, focusing on addressing the underlying metabolic drivers of the disease alongside liver health. Novo said it would buy Akero for $54 a share in cash and an additional $6 if it gets U.S. approval of Efruxifermin - its treatment for fatty liver disease.
Company Overview
Founded: 2017. Headquarters: South San Francisco, US. Ticker: AKRO (NASDAQ).
Industry
Biopharmaceuticals - Metabolic Disease Treatment
Cyborg Score: 8/10 — Strong
Strategically positioned acquisition by Novo Nordisk targeting a multi-billion-dollar MASH market with validated late-stage clinical assets and significant partnership synergies.
Akero's lead product candidate, efruxifermin (EFX), is currently being evaluated in three ongoing Phase 3 clinical studies, building on the results of two Phase 2b clinical trials. The company benefits from Novo Nordisk's backing, a $54 per share acquisition price with additional consideration, and operates in a high-unmet-need market with significant growth potential.
Key Strategic Insights for Akero Therapeutics, Inc.
- Akero has been acquired by Novo Nordisk.
- The MASH market could reach $16 billion by 2033.
- Akero maintained a strong cash position, reporting cash, cash equivalents, and marketable securities of $826.3 million as of September 30, 2024.
- Novo Nordisk planned to submit Phase 3 data to regulators in the first half of 2025.
Recent Developments
- (December 2025) Novo Nordisk acquisition closed
- (October 2025) Definitive acquisition agreement announced with Novo Nordisk
- (January 2025) Announced $300 million public stock offering
Competitors & Competitive Landscape
- Madrigal Pharmaceuticals — First-to-market MASH treatment
- 89bio — FGF21 analog in Phase 3 for MASH
- Novo Nordisk — Weight-loss and metabolic disease treatments
Akero is in a sprint with other biotechs and pharma companies to capture a slice of the growing MASH market, currently cornered by Madrigal Pharmaceuticals' first-to-market product Rezdiffra. Akero is on a similar timeline as fellow biotech 89bio, both of which are in Phase 3 studies.
More Company Research
Sanok Rubber Company Spólka Akcyjna T'way Air Oil States International, Inc. Nitta Corporation Caisse Régionale de Crédit Agricole Mutuel Alpes Provence Société coopérative National Medical Care Company Adeka Corporation Thai Life Insurance Public Company Limited Discovery Silver Corp. Organization of Football Prognostics S.A. Joby Aviation, Inc. Dassault Aviation China Merchants Bank Co., Ltd. Citius Pharmaceuticals, Inc. Tevogen Bio Holdings Inc.Full Company Research Reports
Looking for a more in-depth analysis of Akero Therapeutics, Inc.? AskCyborg's Company Research section contains full AI-generated reports with detailed financials, strategic analysis, and Cyborg Score ratings. Browse the complete company research library or explore industry research reports.
AskCyborg provides AI-powered company research and analysis. Visit AskCyborg for full reports, Cyborg Score ratings, and analyst podcasts.